Understanding How CB1R Binds to New Weight Loss Drugs
Author Information
Author(s): Kumari Punita, Dvorácskó Szabolcs, Enos Michael D., Ramesh Karthik, Lim Darrix, Hassan Sergio A., Kunos George, Cinar Resat, Iyer Malliga R., Rosenbaum Daniel M.
Primary Institution: The University of Texas Southwestern Medical Center
Hypothesis
How do peripherally restricted inverse agonists bind to the cannabinoid receptor 1 (CB1R) and affect its signaling?
Conclusion
The study reveals that new peripherally restricted CB1R inverse agonists can provide weight loss benefits without the negative psychiatric side effects associated with earlier drugs.
Supporting Evidence
- CB1R regulates synaptic transmission and has roles in metabolism.
- Previous CB1R antagonists caused negative psychiatric effects.
- New drugs MRI-1867 and MRI-1891 are designed to avoid these effects.
- High-resolution structures of CB1R with these drugs were determined.
- These structures show how the drugs bind and inhibit CB1R signaling.
Takeaway
Scientists studied how new weight loss drugs interact with a brain receptor to help people lose weight without feeling anxious or depressed.
Methodology
The researchers used cryo-electron microscopy to determine the structures of CB1R bound to the new drugs.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website